Pathoetiology of multiple sclerosis: Are we barking up the wrong tree?

F1000Prime Reports

Volumn 5, Issue , 2013, Pages

  Stys, Peter K ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; IMMUNOGLOBULIN G; MYELIN; PROTEOLIPID PROTEIN; RITUXIMAB; VITAMIN D;

ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; DEMYELINATING DISEASE; ENVIRONMENTAL FACTOR; GENE DELETION; GENETIC ASSOCIATION; GEOGRAPHY; HUMAN; MULTIPLE SCLEROSIS; NONHUMAN;

EID: 84880058467     PISSN: None     EISSN: 20517599     Source Type: Journal    
DOI: 10.12703/P5-20     Document Type: Article

References (82)

1. Kornek B, Lassmann H: Axonal pathology in multiple sclerosis. A historical note. Brain Pathol 1999, 9:651-6. (Pubitemid 29470958)
2. Lassmann H: Multiple sclerosis pathology: evolution of pathogenetic concepts. Brain Pathol 2005, 15:217-22. (Pubitemid 41161177)
3. Prineas JW, Barnard RO, Kwon EE, Sharer LR, Cho ES: Multiple sclerosis: remyelination of nascent lesions. Ann Neurol 1993, 33:137-51. (Pubitemid 23039922)
4. Patrikios P, Stadelmann C, Kutzelnigg A, Rauschka H, Schmidbauer M, Laursen H, Sorensen PS, Brück W, Lucchinetti C, Lassmann H: Remyelination is extensive in a subset of multiple sclerosis patients. Brain 2006, 129:3165-72. (Pubitemid 44871433)
5. Peterson JW, Trapp BD: Neuropathobiology of multiple sclerosis. Neurol Clin 2005, 23:107-29, vi-vii. (Pubitemid 40126917)
6. Geurts J J G, Calabrese M, Fisher E, Rudick RA: Measurement and clinical effect of grey matter pathology in multiple sclerosis. Lancet Neurol 2012, 11:1082-92.
7. Hawkes CH, Macgregor AJ: Twin studies and the heritability of MS: a conclusion. Mult Scler 2009, 15:661-7.
8. Ebers GC: Environmental factors and multiple sclerosis. Lancet Neurol 2008, 7:268-77. (Pubitemid 351222732)
9. Sawcer S, Hellenthal G, Pirinen M, Spencer C C A, Patsopoulos NA, Moutsianas L, Dilthey A, Su Z, Freeman C, Hunt SE, Edkins S, Gray E, Booth DR, Potter SC, Goris A, Band G, Oturai AB, Strange A, Saarela J, Bellenguez C, Fontaine B, Gillman M, Hemmer B, Gwilliam R, Zipp F, Jayakumar A, Martin R, Leslie S, Hawkins S, Giannoulatou E, et al.: Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011, 476:214-9.
10. Kurtzke JF: Epidemiology and etiology of multiple sclerosis. Phys Med Rehabil Clin N Am 2005, 16:327-49. (Pubitemid 40704673)
11. Simpson S, Blizzard L, Otahal P, Van Der Mei I, Taylor B: Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis. J Neurol Neurosurg Psychiatr 2011, 82:1132-41.
12. Koch-Henriksen N, Sørensen PS: The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol 2010, 9:520-32.
13. Ascherio A, Munger KL: Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors. Ann Neurol 2007, 61:504-13. (Pubitemid 47068132)
14. Agrawal SM, Yong VW: Immunopathogenesis of multiple sclerosis. Int Rev Neurobiol 2007, 79:99-126.
15. Smolders J, Damoiseaux J, Menheere P, Hupperts R: Vitamin D as an immune modulator in multiple sclerosis, a review. J Neuroimmunol 2008, 194:7-17.
16. Weinstock-Guttman B, Mehta BK, Ramanathan M, Karmon Y, Henson LJ, Halper J, Riskind P: Vitamin D and multiple sclerosis. Neurologist 2012, 18:179-83.
17. Thacker EL, Mirzaei F, Ascherio A: Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis. Ann Neurol 2006, 59:499-503. (Pubitemid 43358070)
18. Banwell B, Krupp L, Kennedy J, Tellier R, Tenembaum S, Ness J, Belman A, Boiko A, Bykova O, Waubant E, Mah JK, Stoian C, Kremenchutzky M, Bardini MR, Ruggieri M, Rensel M, Hahn J, Weinstock-Guttman B, Yeh EA, Farrell K, Freedman M, Iivanainen M, Sevon M, Bhan V, Dilenge M, Stephens D, Bar-Or A: Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study. Lancet Neurol 2007, 6:773-81. (Pubitemid 47238663)
19. Evans AS: E. B. virus antibody in systemic lupus erythematosus. Lancet 1971, 1:1023-4.
20. Pender MP: Infection of autoreactive B lymphocytes with EBV, causing chronic autoimmune diseases. Trends Immunol 2003, 24:584-8. (Pubitemid 37338526)
21. Giovannoni G, Cutter GR, Lunemann J, Martin R, Münz C, Sriram S, Steiner I, Hammerschlag MR, Gaydos CA: Infectious causes of multiple sclerosis. Lancet Neurol 2006, 5:887-94. (Pubitemid 44715824)
22. Kieseier BC: The mechanism of action of interferon-b in relapsing multiple sclerosis. CNS Drugs 2011, 25:491-502.
23. Fox EJ, Rhoades RW: New treatments and treatment goals for patients with relapsing-remitting multiple sclerosis. Curr Opin Neurol 2012, 25:SII-9.
24. Marta M, Giovannoni G: Disease modifying drugs in multiple sclerosis: mechanisms of action and new drugs in the horizon. CNS Neurol Disord Drug Targets 2012, 11:610-23.
25. Friese MA, Fugger L: Pathogenic CD8 (+) T cells in multiple sclerosis. Ann Neurol 2009, 66:132-41.
26. Wootla B, Eriguchi M, Rodriguez M: Is multiple sclerosis an autoimmune disease? Autoimmune Dis 2012, 2012:969657.
27. Rodriguez M, Scheithauer B: Ultrastructure of multiple sclerosis. Ultrastruct Pathol 1994, 18:3-13. (Pubitemid 24131605)
28. Prineas J: Pathology of the early lesion in multiple sclerosis. Hum Pathol 1975, 6:531-54.
29. Brück W, Schmied M, Suchanek G, Brück Y, Breitschopf H, Poser S, Piddlesden S, Lassmann H: Oligodendrocytes in the early course of multiple sclerosis. Ann Neurol 1994, 35:65-73. (Pubitemid 24027608)
30. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L: Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998, 338:278-85. (Pubitemid 28065253)
31. Seewann A, Vrenken H, Van Der Valk P, Blezer E L A, Knol DL, Castelijns JA, Polman CH, Pouwels P J W, Barkhof F, Geurts J J G: Diffusely abnormal white matter in chronic multiple sclerosis: imaging and histopathologic analysis. Arch Neurol 2009, 66:601-9.
32. Filippi M, Rocca MA, Barkhof F, Brück W, Chen JT, Comi G, De Luca G, De Stefano N, Erickson BJ, Evangelou N, Fazekas F, Geurts J J G, Lucchinetti C, Miller DH, Pelletier D, Popescu B F G, Lassmann H: Association between pathological and MRI findings in multiple sclerosis. Lancet Neurol 2012, 11:349-60.
33. Frischer JM, Bramow S, Dal-Bianco A, Lucchinetti CF, Rauschka H, Schmidbauer M, Laursen H, Sorensen PS, Lassmann H: The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009, 132:1175-89.
34. Strijbis E M M, Inkster B, Vounou M, Naegelin Y, Kappos L, Radue E, Matthews PM, Uitdehaag B M J, Barkhof F, Polman CH, Montana G, Geurts J J G: Glutamate gene polymorphisms predict brain volumes in multiple sclerosis. Mult Scler 2013, 19:281-8.
35. Coles AJ, Wing MG, Molyneux P, Paolillo A, Davie CM, Hale G, Miller D, Waldmann H, Compston A: Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 1999, 46:296-304. (Pubitemid 29416266)
36. Jones JL, Coles AJ: Spotlight on alemtuzumab. Int MS J 2009, 16:77-81.
37. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, Langer-Gould A, Smith CH: B-cell depletion with rituximab in relapsingremitting multiple sclerosis. N Engl J Med 2008, 358:676-88. (Pubitemid 351240747)
38. Hawker K, O'Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, Hauser S, Waubant E, Vollmer T, Panitch H, Zhang J, Chin P, Smith CH: Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009, 66:460-71.
39. Hochmeister S, Grundtner R, Bauer J, Engelhardt B, Lyck R, Gordon G, Korosec T, Kutzelnigg A, Berger JJ, Bradl M, Bittner RE, Lassmann H: Dysferlin is a new marker for leaky brain blood vessels in multiple sclerosis. J Neuropathol Exp Neurol 2006, 65:855-65. (Pubitemid 44371231)
40. Lemere CA, Masliah E: Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat Rev Neurol 2010, 6:108-19.
41. Mancardi G, Saccardi R: Autologous haematopoietic stem-cell transplantation in multiple sclerosis. Lancet Neurol 2008, 7:626-36.
42. Smith KJ, Lassmann H: The role of nitric oxide in multiple sclerosis. Lancet Neurol 2002, 1:232-41. (Pubitemid 37159185)
43. Howe CL, Adelson JD, Rodriguez M: Absence of perforin expression confers axonal protection despite demyelination. Neurobiol Dis 2007, 25:354-9. (Pubitemid 46124015)
44. Siffrin V, Vogt J, Radbruch H, Nitsch R, Zipp F: Multiple sclerosis - candidate mechanisms underlying CNS atrophy. Trends Neurosci 2010, 33:202-10.
45. Matute C: Glutamate and ATP signalling in white matter pathology. J Anat 2011, 219:53-64.
46. Stys PK, Zamponi GW, Van Minnen J, Geurts J J G: Will the real multiple sclerosis please stand up? Nat Rev Neurosci 2012, 13:507-14.
47. Kerbrat A, Aubert-Broche B, Fonov V, Narayanan S, Sled JG, Arnold DA, Banwell B, Collins DL: Reduced head and brain size for age and disproportionately smaller thalami in child-onset MS. Neurology 2012, 78:194-201.
48. Wenning GK, Stefanova N, Jellinger KA, Poewe W, Schlossmacher MG: Multiple system atrophy: a primary oligodendrogliopathy. Ann Neurol 2008, 64:239-46.
49. Nave K, Trapp BD: Axon-glial signaling and the glial support of axon function. Annu Rev Neurosci 2008, 31:535-61.
50. Nave K: Myelination and support of axonal integrity by glia. Nature 2010, 468:244-52.
51. Warshawsky I, Rudick RA, Staugaitis SM, Natowicz MR: Primary progressive multiple sclerosis as a phenotype of a PLPI gene mutation. Ann Neurol 2005, 58:470-3. (Pubitemid 41266636)
52. Cao L, Sun D, Whitaker JN: Citrullinated myelin basic protein induces experimental autoimmune encephalomyelitis in Lewis rats through a diverse T cell repertoire. J Neuroimmunol 1998, 88:21-9. (Pubitemid 28342899)
53. Moscarello MA, Mastronardi FG, Wood DD: The role of citrullinated proteins suggests a novel mechanism in the pathogenesis of multiple sclerosis. Neurochem Res 2007, 32:251-6. (Pubitemid 46238870)
54. Kanter JL, Narayana S, Ho PP, Catz I, Warren KG, Sobel RA, Steinman L, Robinson WH: Lipid microarrays identify key mediators of autoimmune brain inflammation. Nat Med 2006, 12:138-43. (Pubitemid 43050089)
55. Sriram S, Steiner I: Experimental allergic encephalomyelitis: a misleading model of multiple sclerosis. Ann Neurol 2005, 58:939-45. (Pubitemid 41746884)
56. Palace J: Multiple sclerosis associated with Leber's Hereditary Optic Neuropathy. J Neurol Sci 2009, 286:24-7.
57. Kovacs GG, Höftberger R, Majtényi K, Horvath R, Barsi P, Komoly S, Lassmann H, Budka H, Jakab G: Neuropathology of white matter disease in Leber's hereditary optic neuropathy. Brain 2005, 128:35-41. (Pubitemid 40070518)
58. Itoh M, Hayashi M, Fujioka Y, Nagashima K, Morimatsu Y, Matsuyama H: Immunohistological study of globoid cell leukodystrophy. Brain Dev 2002, 24:284-90. (Pubitemid 34828383)
59. Moser HW: Adrenoleukodystrophy: phenotype, genetics, pathogenesis and therapy. Brain 1997, 120(Pt 8):1485-508. (Pubitemid 27344713)
60. Stöckler S, Millner M, Molzer B, Ebner F, Körner E, Moser HW: Multiple sclerosis-like syndrome in a woman heterozygous for adrenoleukodystrophy. Eur Neurol 1993, 33:390-2. (Pubitemid 23283706)
61. Dooley JM, Wright BA: Adrenoleukodystrophy mimicking multiple sclerosis. Can J Neurol Sci 1985, 12:73-4. (Pubitemid 15130925)
62. Picard F, Guidoux S, Martin T, Aubourg P, Pasquali J: T-cell receptor Vbeta gene usage in CSF lymphocytes in X-linked adrenoleukodystrophy. J Mol Recognit 2005, 18:254-61. (Pubitemid 40697630)
63. Junker A, Ivanidze J, Malotka J, Eiglmeier I, Lassmann H, Wekerle H, Meinl E, Hohlfeld R, Dornmair K: Multiple sclerosis: T-cell receptor expression in distinct brain regions. Brain 2007, 130:2789-99. (Pubitemid 350033964)
64. Babbe H, Roers A, Waisman A, Lassmann H, Goebels N, Hohlfeld R, Friese M, Schröder R, Deckert M, Schmidt S, Ravid R, Rajewsky K: Clonal expansions of CD8 (+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med 2000, 192:393-404. (Pubitemid 30629164)
65. Ito M, Blumberg BM, Mock DJ, Goodman AD, Moser AB, Moser HW, Smith KD, Powers JM: Potential environmental and host participants in the early white matter lesion of adrenoleukodystrophy: morphologic evidence for CD8 cytotoxic T cells, cytolysis of oligodendrocytes, and CDl-mediated lipid antigen presentation. J Neuropathol Exp Neurol 2001, 60:1004-19. (Pubitemid 32924126)
66. Kemp S, Berger J, Aubourg P: X-linked adrenoleukodystrophy: clinical, metabolic, genetic and pathophysiological aspects. Biochim Biophys Acta 2012, 1822:1465-74.
67. Powers JM, De Ciero DP, Ito M, Moser AB, Moser HW: Adrenomyeloneuropathy: a neuropathologic review featuring its noninflammatory myelopathy. J Neuropathol Exp Neurol 2000, 59:89-102. (Pubitemid 30106465)
68. Mar. S, Noetzel M: Axonal damage in leukodystrophies. Pediatr Neurol 2010, 42:239-42.
69. Van Der Knaap MS, Pronk JC, Scheper GC: Vanishing white matter disease. Lancet Neurol 2006, 5:413-23.
70. Brück W, Herms J, Brockmann K, Schulz-Schaeffer W, Hanefeld F: Myelinopathia centralis diffusa (vanishing white matter disease): evidence of apoptotic oligodendrocyte degeneration in early lesion development. Ann Neurol 2001, 50:532-6. (Pubitemid 32938899)
71. Englund E, Brun A, Alling C: White matter changes in dementia of Alzheimer's type. Biochemical and neuropathological correlates. Brain 1988, 111(Pt 6):1425-39. (Pubitemid 19028461)
72. Boraschi D, Del Giudice G, Dutel C, Ivanoff B, Rappuoli R, Grubeck-Loebenstein B: Ageing and immunity: addressing immune senescence to ensure healthy ageing. Vaccine 2010, 28:3627-31.
73. Benilova I, Karran E, De Strooper B: The toxic Aß oligomer and Alzheimer's disease: an emperor in need of clothes. Nat Neurosci 2012, 15:349-57.
74. Grant JL, Ghosn E E B, Axtell RC, Herges K, Kuipers HF, Woodling NS, Andreasson K, Herzenberg LA, Herzenberg LA, Steinman L: Reversal of paralysis and reduced inflammation from peripheral administration of β-amyloid in THI and THI7 versions of experimental autoimmune encephalomyelitis. Sci Transl Med 2012, 4:145ra105.
75. Locatelli G, Wörtge S, Buch T, Ingold B, Frommer F, Sobottka B, Krüger M, Karram K, Bühlmann C, Bechmann I, Heppner FL, Waisman A, Becher B: Primary oligodendrocyte death does not elicit anti-CNS immunity. Nat Neurosci 2012, 15:543-50.
76. Ip CW, Kroner A, Bendszus M, Leder C, Kobsar I, Fischer S, Wiendl H, Nave K, Martini R: Immune cells contribute to myelin degeneration and axonopathic changes in mice overexpressing proteolipid protein in oligodendrocytes. J Neurosci 2006, 26:8206-16. (Pubitemid 44315145)
77. Kassmann CM, Lappe-Siefke C, Baes M, Brügger B, Mildner A, Werner HB, Natt O, Michaelis T, Prinz M, Frahm J, Nave K: Axonal loss and neuroinflammation caused by peroxisome-deficient oligodendrocytes. Nat Genet 2007, 39:969-76. (Pubitemid 47185174)
78. Wieser GL, Gerwig UC, Adamcio B, Barrette B, Nave K, Ehrenreich H, Goebbels S: Neuroinflammation in white matter tracts of Cnpl mutant mice amplified by a minor brain injury. Glia 2013, 61:869-80.
79. Buch T, Heppner FL, Tertilt C, Heinen T J AJ, Kremer M, Wunderlich FT, Jung S, Waisman A: A Cre-inducible diphtheria toxin receptor mediates cell lineage ablation after toxin administration. Nat Methods 2005, 2:419-26. (Pubitemid 40916560)
80. Barnett MH, Prineas JW: Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol 2004, 55:458-68. (Pubitemid 38391962)
81. Salter MG, Fern R: NMDA receptors are expressed in developing oligodendrocyte processes and mediate injury. Nature 2005, 438:1167-71. (Pubitemid 41831687)
82. Micu I, Jiang Q, Coderre E, Ridsdale A, Zhang L, Woulfe J, Yin X, Trapp BD, McRory JE, Rehak R, Zamponi GW, Wang W, Stys PK: NMDA receptors mediate calcium accumulation in myelin during chemical ischaemia. Nature 2006, 439:988-92. (Pubitemid 43292418)